Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oppenheimer

Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?

Wave Life Sciences stock sinks as Phase 1 data for obesity drug disappoints investors. But Oppenheimer still recommends loading up on WVE shares today.

Barchart

Oppenheimer Is Bullish on Target Hospitality Stock Amid Major Data Center Pivot: Analysts Call for 16% Upside

Target Hospitality is gaining fresh Wall Street support as its shift toward housing workers tied to AI data center and power infrastructure starts to reshape its growth story.

Barchart

Project Hail Mary Blasted Off On Opening Night (And Christopher Nolan Better Watch Out)

Project Hail Mary is off to an explosive start at the box office.

Cinemablend

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Extend Weekly Losing Streak: Stock Market Today

Efforts to boost crude supplies did little to stem worries of rising oil prices and inflation ahead of next week's Fed meeting.

Kiplinger

'Some of the best 4K Blu-rays I've ever tested' — Gruv is having a 3 for $39 4K Blu-ray sale, and I've picked the 6 best discs, all of which I've personally tested

Gruv's 3 for $39 4K Blu-ray sale is incredible value and it features some of the best 4K discs I've tested!

TechRadar

I tested three compact Dolby Atmos soundbars from Sonos, Sony and Denon — this is the one I'd buy with my own money

Three compact Dolby Atmos soundbars, the same five movie scenes — which ones come out on top?

TechRadar

Dear Vertiv Stock Fans, Mark Your Calendars for March 23

Vertiv shares rally ahead of inclusion in the S&P 500 index on Mar. 23. Oppenheimer explains why VRT stock remains worth owning in 2026.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Why Oppenheimer Says Oracle Stock Can Gain 25% from Here

Oppenheimer has initiated coverage of ORCL stock with a $185 price target.

Barchart

Are the Best Days Over for IBM Stock? What Price Volatility Tells Us and How You Can Trade IBM Now.

IBM’s volume was three times its 30-day average yesterday. It also had a high standard deviation of -3.46. Big moves are the norm for IBM; this latest decline suggests the good times could be over.

Barchart

Why 1 Analyst Is Betting on 30% Upside for This Beaten-Down Software Stock

Oppenheimer’s analyst sees notable upside in Unity as the company’s strengthening fundamentals outweigh AI disruption fears.

Barchart

"The loss of a studio is a huge blow": Christopher Nolan says he has "very, very significant concerns" about the Warner Bros. Netflix sale

Christopher Nolan speaks out about Netflix buying Warner Bros. as the new president of the DGA

Total Film

Christopher Nolan Gets Real About Netflix's Warner Bros. Acquisition Being A ‘Huge Blow’

This is a major shakeup in Hollywood.

Cinemablend

This Old-School Company Is Up 100% on AI Demand. Should You Buy Shares Now?

With shares of this old-school glass pioneer soaring triple digits over the past year, can the AI-driven momentum push the stock even higher?

Barchart

That Time Emily Blunt Gave David Krumholtz Some Solid Hollywood Advice (That Supergirl Promptly Ignored)

Sometimes you have to “trust the process."

Cinemablend

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

H200 Component Production Is Halted. What That Means for Nvidia, and Should You Buy the NVDA Stock Dip Here?

Nvidia stock sinks on reports the company’s suppliers have halted production of H200 components. But Oppenheimer continues to recommend buying NVDA shares in 2026.

Cinemablend

Christopher Nolan Is Delivering A Special Sneak Peek At The Odyssey, And You'll Be Able To See It Very Soon

Brace yourselves for an epic.

Benzinga

Broadcom To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Broadcom Snaps Up Half Of Samsung's HBM Output For Google AI Chips

Broadcom Inc (NASDAQ:AVGO) stock has gained over 64% year-to-date as its application-specific integrated circuits (ASICs), custom chips designed for artificial intelligence (AI) and high-performance computing, gain traction powered by the AI frenzy.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?

Amazon’s flat 2025 performance may be setting up a breakout year. With bullish analyst calls, rising AWS momentum, and a low P/E, it looks ready to run.

Barchart

Analysts Say AWS Will Drive ‘Significant Upside’ for Amazon. Should You Buy AMZN Stock Now?

Oppenheimer raised its price target on Amazon ahead of expectations for increased AWS upside.

Benzinga

Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Barchart

Oppenheimer Thinks Investors Are Missing Out on IBM Stock

Oppenheimer analyst believes investors are underestimating IBM’s rising strength in the AI-driven tech world.

Benzinga

Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations